ATHE (Alterity Therapeutics) Net Profit

Official company branding of alteritytherapeutics.com (ATHE)

Alterity Therapeutics (ATHE) is integrating ESG standards and bioethics into the development of neurological drugs while reducing chemical waste. Analyzing the company's current profit on GURU.Markets, we see that the current level is -0.02, linking environmental sustainability with the development of treatments for Alzheimer's and Parkinson's diseases. However, the absence of profitable assets and operating cash flow creates a business dependency on existing cash reserves.

ATHE: alteritytherapeutics.com Net Income 07/04/2022 - 10/31/2026

Analytical breakdowns and data insights for company alteritytherapeutics.com (ATHE)

- stock value and consensus price forecast:
Market Price Alterity Therapeutics Limited|ATHE - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Alterity Therapeutics Limited|ATHE - Total Company Value
- book capitalization data:
Net Assets per Single Share Alterity Therapeutics|ATHE - Company Net Assets|Market Cap to Book Value Multiple alteritytherapeutics.com|ATHE - Company Total Assets
- debt and liquidity details:
Debt to Capital Alterity Therapeutics|ATHE - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Alterity Therapeutics Limited|ATHE - Company Aggregate Debts|Debts to Net Assets Alterity Therapeutics Limited|ATHE - Company Long-Term Liabilities|Amount of Current Liabilities Alterity Therapeutics|Immediate Liquidity alteritytherapeutics.com
- earnings and valuation multiples information:
ATHE - Net Income
Fundamental valuation:ATHE - Alterity Therapeutics Ltd
Signature product of Alterity Therapeutics Ltd.

This indicator objectively measures daily net profit and equity value, allowing for an assessment of the fundamental potential for business expansion and the risks of overvalued quotes. Analyzing the operating net profit of Alterity Therapeutics (ATHE) helps benchmark the company's financial stability against its progress in developing innovative drugs for Parkinson's disease therapy and the publication of early-stage clinical trial results.

Key competitors

Company Net Income Biogen Idec (BIIB)|NBIX (Neurocrine Biosciences) - Net Profit|Net Profit regencellbioscience.com|Company Net Income Axsome Therapeutics, Inc. (AXSM)|Company Net Income ACAD (ACADIA Pharma)|Xenon Pharmaceuticals Inc - Net Income|Profit After Payment of Taxes VKTX (Viking Therapeutics Corp)|Supernus Pharmaceuticals - Net Profit|Company Net Income catalystpharma.com|Denali Therapeutics Inc. (DNLI) - Company Net Income|Harmony Biosciences Inc - Final Profit|BHVN (Biohaven Pharmaceutical) - Net Profit|Amylyx Corp (AMLX) - Net Financial Result|Net Income TRVI (Trevi Therapeutics)|Profit After Payment of Taxes PRAX|Anavex Life Sciences Corp. - Net Income|CeriBell Inc (CBLL) - Company Net Income|PRTA: Net Income|Final Profit ALEC (Alector, Inc.)|ANNX (Annexon, Inc.) - Net Income|OMER: Profit After Payment of Taxes|NGNE (Neurogene) - Net Profit|ACIU: Final Profit|Net Profit VYGR|NMRA - Company Net Income|Company Net Income Scilex Holding Company SCLX|Final Profit TVGN|Alpha Cognition Corp - Net Profit|CGTX - Net Profit|Inhibikase (IKT) - Company Net Income|Profit After Tax SAVA (Cassava Pharma)|ASRT (Assertio Holdings) - Net Profit|Company Net Income Coya COYA|Net Income VTGN (Vistagen Therapeutics)|Net Profit ovidrx.com (OVID)|Acumen Pharma - Net Income|Profit After Payment of Taxes CRVO (CervoMed Corporation)|Clene Nanomedicine - Net Profit|Net Financial Result PepGen Inc. PEPG|JUNS: Net Profit|Net Income Relmada Therapeutics Inc|Company Net Income Annovis Bio Corp|Grace Tx (GRCE) - Net Financial Result|Net Profit AIFF|Net Profit anewmeds.com (KLTO)|NeuroSense Therapeutics Ltd. - Net Income|Profit After Payment of Taxes RVPH (Reviva Pharmaceuticals Holdings Inc.)|MetaVia, Inc. - Net Profit|Final Profit NRXS (NeurAxis Inc)|HSDT: Net Profit|Company Net Income Passage Bio (PASG)|Company Net Income Neuphoria Therapeutics, Inc.|Company Profit NERV (Minerva Neurosciences Inc)|Net Profit ATHA|ADXN - Company Net Income|Alzamend Neuro - Net Income|Net Profit Cyclerion Therapeutics Inc. CYCN|PTIX - Company Net Income|Final Profit KTTA (Pasithea Therapeutics)|cortigent.com (CRGT) - Company Net Income|Company Net Income Avenue Therapeutics Inc (ATXI)|BCLI (Brainstorm Cell) - Net Profit|Net Profit caratherapeutics.com|Company Net Income Chromocell Therapeutics Corp. (CHRO)|Company Net Income ELYM (eliemtx.com)|Intra-Cellular Therapies, Inc. - Net Income|Profit After Payment of Taxes LBPH (Longboard)|Marinus Pharmaceuticals - Net Profit|Company Net Income nkgenbiotech.com|NeuroBo Pharmaceuticals, Inc. (NRBO) - Company Net Income|Sage Therapeutics Inc. - Final Profit|SNPX (Neurotrope) - Net Profit|Trevena Inc (TRVN) - Net Financial Result|Net Income VIGL (Vigil Neuroscience)|Profit After Payment of Taxes WENA|Cerevel Therapeutics, Inc. - Net Income